0000899243-19-007975.txt : 20190315
0000899243-19-007975.hdr.sgml : 20190315
20190315163921
ACCESSION NUMBER: 0000899243-19-007975
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190313
FILED AS OF DATE: 20190315
DATE AS OF CHANGE: 20190315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mostafa Adam S.
CENTRAL INDEX KEY: 0001738081
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 19685539
MAIL ADDRESS:
STREET 1: C/O ABPRO CORPORATION
STREET 2: 65 CUMMINGS PARK DRIVE
CITY: WOBURN
STATE: MA
ZIP: 01801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 955 MASSACHUSETTS AVENUE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 955 MASSACHUSETTS AVENUE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2019-03-13
2019-03-14
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0001738081
Mostafa Adam S.
C/O X4 PHARMACEUTICALS, INC.
955 MASSACHUSETTS AVENUE, 4TH FLOOR
CAMBRIDGE
MA
0
1
0
0
See Remarks
Stock Option (right to buy)
10.44
2019-03-13
4
A
0
62633
A
2028-10-03
Common Stock
62633
62633
D
Twenty-five percent (25%) of the shares subject to the option shall vest on September 5, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. This amendment is being filed solely to correct the vesting schedule of the option included in the Form 4 filed on March 14, 2019.
Reflects the Reporting Person's stock option to acquire 659,067 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger").
Chief Financial Officer and Treasurer
All share and per share amounts of the Issuer's common stock and stock options reported in this Form 4 reflect the 1-for-6 reverse stock split of the Issuer's common stock effected on March 13, 2019 after the completion of the Merger.
/s/ Adam S. Mostafa
2019-03-15